Tiltan Pharma

Company Overview

Snapshot

Founded in January 2006 by Yigal Stav and Shmuel (Muli) Ben-Sasson, Tiltan Pharma operated with 11–50 employees. The company raised $1.5M across one funding round from Integra Holdings. In February 2014, Tiltan Pharma secured $1.5M in seed funding.

Business overview

Tiltan Pharma was a biopharmaceutical company focused on developing proprietary anti-angiogenic and immune modulatory platforms for cancer treatment. Its core product, TL-118, was an oral drug combination designed with anticancer, anti-angiogenic, and immune modulatory properties. This therapy repurposed four approved drugs with known safety profiles into a low-dose, high-frequency regimen. The company served the pharmaceuticals market, specifically within the Health Tech & Life Sciences sector, with a focus on drugs discovery and development for oncology patients.

Company Intelligence Q&A

What was Tiltan Pharma's primary focus?

Tiltan Pharma focused on developing proprietary anti-angiogenic and immune modulatory platforms for cancer treatment.

What was the company's leading product?

The company's leading product was TL-118, an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties.

When was Tiltan Pharma founded and by whom?

Tiltan Pharma was founded in January 2006 by Yigal Stav and Shmuel (Muli) Ben-Sasson.

What was the status of clinical trials for TL-118?

Tiltan Pharma was conducting a randomized, open-label phase-IIb clinical trial for TL-118 in metastatic pancreatic cancer under an FDA-approved investigational new drug application.

When did Tiltan Pharma cease operations?

Tiltan Pharma ceased to operate in September 2019.